feed,title,long_url,short_url
Benzinga,PDS Biotech's Lead Versamune Program Achieves Overall Tumor Reduction of 67% In HPV16 Positive Cancer Patients,https://benzinga.com/general/biotech/21/06/21467762/pds-biotechs-lead-versamune-program-achieves-overall-tumor-reduction-of-67-in-hpv16-positive-canc,https://j.mp/3coGlpm
